HER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer
Discrepancy in the HER2 status of the metastases and of CTCs was observed in approximately one-third of patients. Measuring HER2 on CTCs could potentially offer a means to longitudinally monitor HER2 status during therapy and simultaneously address challenges such as tumor heterogeneity. Therefore, the predictive value of HER2 on CTCs should be further investigated in clinical trials.
Authors
- Laura L. Michel (ORCID: https://orcid.org/0000-0002-7784-2826)
- Hugo Clemente
- Klaus Pantel (ORCID: https://orcid.org/0000-0001-5736-2772)
- Kathrin Haßdenteufel (ORCID: https://orcid.org/0000-0003-0141-7425)
- Thomas Maximilian Deutsch (ORCID: https://orcid.org/0000-0003-0621-1290)
- Carlo Fremd (ORCID: https://orcid.org/0000-0002-7840-430X)
- Anna Sophie Scholz (ORCID: https://orcid.org/0000-0002-3439-3872)
- Katharina Smetanay (ORCID: https://orcid.org/0000-0003-2881-5183)
- Verena Thewes
- Sabine Riethdorf (ORCID: https://orcid.org/0000-0003-0028-5643)
- Andreas Trumpp (ORCID: https://orcid.org/0000-0002-6212-3466)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- Lara Meike Tretschock (ORCID: https://orcid.org/0009-0002-6381-0978)
Institutions
- Universität Hamburg (DE)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- National Center for Tumor Diseases (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1159/000542830
- Citations
- 2
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.57